BackEdwards Lifesciences Overview
Edwards Lifesciences Corp

Edwards Lifesciences Target Price

See Edwards Lifesciences's analyst price targets ($100) vs the current share price.

Get informed when a big investor buys or sells

+ Follow

Share Price

$89.6

Average Target Price

$100.0011.6% upside

13 analysts in the last 4 months

High: $110 | Low: $85

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-07-28UBS$11022.8% upsideOpen
2026-07-24Leerink PartnersMike Kratky$10112.7% upsideOpen
2026-07-24Piper Sandler$10112.7% upsideOpen
2026-07-16Truist FinancialRichard Newitter$956% upsideOpen
2026-07-13RBC Capital$11022.8% upsideOpen
2026-07-06Evercore ISI$10011.6% upsideOpen
2026-06-30BTIGMarie Thibault$11022.8% upsideOpen
2026-04-27Barclays$11022.8% upsideOpen
2026-04-24Truist Financial$900.4% upsideOpen
2026-04-24Canaccord GenuityWilliam Plovanic$855.1% downsideOpen
2026-04-24BTIG$10011.6% upsideOpen
2026-04-24Evercore ISIVijay Kumar$933.8% upsideOpen
2026-04-13Mizuho Securities$956% upsideOpen
2026-02-11Goldman SachsDavid Roman$956% upsideOpen
2026-02-11Piper Sandler$10011.6% upsideOpen
2026-02-11Truist FinancialRichard Newitter$890.7% downsideOpen
2026-02-04UBSDanielle Antalffy$944.9% upsideOpen
2026-01-20Stifel Nicolaus$11022.8% upsideOpen
2026-01-20Piper Sandler$989.4% upsideOpen
2026-01-12Barclays$10416.1% upsideOpen
2026-01-12Robert W. Baird$900.4% upsideOpen
2026-01-12UBSDanielle Antalffy$956% upsideOpen
2026-01-09Goldman SachsDavid Roman$10820.5% upsideOpen
2026-01-07Stifel NicolausRick Wise$10517.2% upsideOpen
2026-01-05Evercore ISI$944.9% upsideOpen
2025-12-18Wells Fargo$10011.6% upsideOpen
2025-12-17Canaccord GenuityWilliam Plovanic$872.9% downsideOpen
2025-12-16Robert W. BairdDavid Rescott$872.9% downsideOpen
2025-12-08Barclays$10315% upsideOpen
2025-12-05RBC CapitalShagun Singh$10011.6% upsideOpen
2025-12-05Robert W. BairdDavid Rescott$881.8% downsideOpen
2025-12-05Truist FinancialRichard Newitter$922.7% upsideOpen
2025-12-05UBS$922.7% upsideOpen
2025-12-05Stifel NicolausRick Wise$10011.6% upsideOpen
2025-12-05Wells FargoLarry Biegelsen$967.1% upsideOpen
2025-12-05Canaccord GenuityWilliam Plovanic$890.7% downsideOpen
2025-12-04BTIGMarie Thibault$10315% upsideOpen
2025-11-03BernsteinLee Hambright$900.4% upsideOpen
2025-11-03Raymond JamesJayson Bedford$967.1% upsideOpen
2025-11-03Canaccord GenuityWilliam Plovanic$846.2% downsideOpen
2025-11-03UBS$900.4% upsideOpen
2025-10-31Robert W. BairdDavid Rescott$837.4% downsideOpen
2025-10-31RBC Capital$956% upsideOpen
2025-10-31Goldman Sachs$10416.1% upsideOpen
2025-10-31National Bank$922.7% upsideOpen
2025-10-31Barclays$9910.5% upsideOpen
2025-10-29JefferiesMatthew Taylor$989.4% upsideOpen
2025-10-28Truist Financial$872.9% downsideOpen
2025-10-27Truist Financial$828.5% downsideOpen
2025-10-07Evercore ISI$881.8% downsideOpen

Edwards Lifesciences (EW) FAQ

Edwards Lifesciences posts a target price of $100. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

A target price of $100 for EW means covering analysts, on average, see the stock 11.6% upside of $89.6 over about 12 months. Dig into who set the high and low targets and how recently they updated — freshness matters as much as the average itself.

Context for EW's target price usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Edwards Lifesciences's other metric pages and overview cover the third.

Judging Edwards Lifesciences against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in target price easier to interpret. Start with $100 here, then scan peer and history charts to see if the gap is persistent.